T. ELVERDİ Et Al. , "Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?," EXPERT REVIEW OF CLINICAL PHARMACOLOGY , vol.14, pp.1183-1188, 2021
ELVERDİ, T. Et Al. 2021. Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?. EXPERT REVIEW OF CLINICAL PHARMACOLOGY , vol.14 , 1183-1188.
ELVERDİ, T., Ozer Cerme, M. D., Aydin, T., & EŞKAZAN, A. E., (2021). Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?. EXPERT REVIEW OF CLINICAL PHARMACOLOGY , vol.14, 1183-1188.
ELVERDİ, Tuğrul Et Al. "Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?," EXPERT REVIEW OF CLINICAL PHARMACOLOGY , vol.14, 1183-1188, 2021
ELVERDİ, Tuğrul Et Al. "Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?." EXPERT REVIEW OF CLINICAL PHARMACOLOGY , vol.14, pp.1183-1188, 2021
ELVERDİ, T. Et Al. (2021) . "Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?." EXPERT REVIEW OF CLINICAL PHARMACOLOGY , vol.14, pp.1183-1188.
@article{article, author={Tuğrul ELVERDİ Et Al. }, title={Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?}, journal={EXPERT REVIEW OF CLINICAL PHARMACOLOGY}, year=2021, pages={1183-1188} }